Cantor Fitzgerald Reiterates Buy Rating for BioCryst Pharmaceuticals
Cantor Fitzgerald maintains its buy rating on BioCryst Pharmaceuticals with a $29 price target, a 190% upside from the current price.
Key Points
- Cantor Fitzgerald reiterated its buy rating on BioCryst Pharmaceuticals, Inc. (BCRX) with a target price of $29 on June 30, 2026.
- Cantor Fitzgerald's $29 price target implies 190% upside from BioCryst Pharmaceuticals, Inc.'s ($BCRX) current $10 share price.
- Shares of BioCryst traded at $9.55 on Tuesday, with a market cap of approximately $2.53 billion and a forward P/E ratio of 14.6.
- Insider buying activity included purchases by Steven Galson and Machelle Sanders on June 11, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Cantor Fitzgerald has reiterated its buy rating on BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX), maintaining a price target of $29. This announcement was made on June 30, 2026, by analyst Steven Seedhouse. On that same day, shares of BioCryst traded at $9.55.
Cantor Fitzgerald vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
BioCryst Pharmaceuticals, Inc. Stock Up 1.8%
On Tuesday, BioCryst Pharmaceuticals' stock traded near $9.55. The company, which operates in the healthcare sector, boasts a market capitalization of about $2.53 billion. It has a forward P/E ratio of 14.6 and a beta of 0.565, indicating lower volatility compared to the broader market. Over the past 52 weeks, the stock has ranged from a low of $6.00 to a high of $10.94. Its 50-day moving average is $8.92, while the 200-day moving average stands at $7.97.
$BCRX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
BioCryst Pharmaceuticals reported revenue of $885.7 million, reflecting a growth rate of 7.5%. Despite this, the company has a net margin of -51.7%, indicating it is not currently profitable. Earnings per share stand at -$1.77. Investors can look forward to the next earnings announcement on August 3, 2026.
Insider Buying and Selling at BioCryst Pharmaceuticals, Inc.
There has been notable insider buying activity at BioCryst Pharmaceuticals. On June 11, 2026, several insiders, including Steven Galson and Machelle Sanders, purchased shares. Galson bought 33,540 shares, while Sanders acquired 15,294 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 30, 2026, Cantor Fitzgerald maintained its buy rating for BioCryst Pharmaceuticals with a $29 price target. Other analysts have also shown interest in the stock. For instance, Citizens maintained a buy rating with a $28 target on May 7, 2026, and Wedbush set a $21 target on the same day. In total, there are 10 analyst opinions, with a mean target price of $21.30.
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotechnology company based in Durham, North Carolina. It focuses on developing and commercializing medicines for rare diseases, including hereditary angioedema (HAE). The company markets ORLADEYO, an oral treatment for HAE, and is working on other therapeutic candidates like Navenibart and BCX17725. Under the leadership of CEO Charles K. Gayer, BioCryst employs 435 people.
Bottom Line
Cantor Fitzgerald's reiterated buy rating reflects continued confidence in BioCryst Pharmaceuticals' prospects. Investors watch these analyst ratings closely for insights into a company's potential. It's important to remember that these ratings are based on backward-looking data and may not reflect current market conditions.
Get BioCryst Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BCRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.